Literature DB >> 22210875

Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.

Liqiang Xi1, Evgeny Arons, Winnifred Navarro, Katherine R Calvo, Maryalice Stetler-Stevenson, Mark Raffeld, Robert J Kreitman.   

Abstract

Recently, the BRAF V600E mutation was reported in all cases of hairy cell leukemia (HCL) but not in other peripheral B-cell neoplasms. We wished to confirm these results and assess BRAF status in well-characterized cases of HCL associated with poor prognosis, including the immunophenotypically defined HCL variant (HCLv) and HCL expressing the IGHV4-34 immunoglobulin rearrangement. Fifty-three classic HCL (HCLc) and 16 HCLv cases were analyzed for BRAF, including 5 HCLc and 8 HCLv expressing IGHV4-34. BRAF was mutated in 42 (79%) HCLc, but wild-type in 11 (21%) HCLc and 16 (100%) HCLv. All 13 IGHV4-34(+) HCLs were wild-type. IGHV gene usage in the 11 HCLc BRAF wild-type cases included 5 IGHV4-34, 5 other, and 1 unknown. Our results suggest that HCLv and IGHV4-34(+) HCLs have a different pathogenesis than HCLc and that a significant minority of other HCLc are also wild-type for BRAF V600.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22210875      PMCID: PMC3321859          DOI: 10.1182/blood-2011-09-379339

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

Review 1.  Immunophenotyping and differential diagnosis of hairy cell leukemia.

Authors:  Estella Matutes
Journal:  Hematol Oncol Clin North Am       Date:  2006-10       Impact factor: 3.722

2.  Eradication of minimal residual disease in hairy cell leukemia.

Authors:  Farhad Ravandi; Jeffrey L Jorgensen; Susan M O'Brien; Srdan Verstovsek; Charles A Koller; Stefan Faderl; Francis J Giles; Alessandra Ferrajoli; William G Wierda; Shirley Odinga; Xuelin Huang; Deborah A Thomas; Emil J Freireich; Dan Jones; Michael J Keating; Hagop M Kantarjian
Journal:  Blood       Date:  2006-02-23       Impact factor: 22.113

3.  Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing.

Authors:  Jin Li; Lilin Wang; Harvey Mamon; Matthew H Kulke; Ross Berbeco; G Mike Makrigiorgos
Journal:  Nat Med       Date:  2008-04-13       Impact factor: 53.440

4.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

Authors:  Edna T Kimura; Marina N Nikiforova; Zhaowen Zhu; Jeffrey A Knauf; Yuri E Nikiforov; James A Fagin
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

5.  Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.

Authors:  R J Kreitman; W H Wilson; K Bergeron; M Raggio; M Stetler-Stevenson; D J FitzGerald; I Pastan
Journal:  N Engl J Med       Date:  2001-07-26       Impact factor: 91.245

6.  A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia.

Authors:  J C Cawley; G F Burns; F G Hayhoe
Journal:  Leuk Res       Date:  1980       Impact factor: 3.156

7.  Chromosomal assignment of two human B-raf(Rmil) proto-oncogene loci: B-raf-1 encoding the p94Braf/Rmil and B-raf-2, a processed pseudogene.

Authors:  A Eychène; J V Barnier; F Apiou; B Dutrillaux; G Calothy
Journal:  Oncogene       Date:  1992-08       Impact factor: 9.867

8.  Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.

Authors:  Grant R Goodman; Carol Burian; James A Koziol; Alan Saven
Journal:  J Clin Oncol       Date:  2003-03-01       Impact factor: 44.544

9.  Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1).

Authors:  Brunangelo Falini; Enrico Tiacci; Arcangelo Liso; Katia Basso; Elena Sabattini; Roberta Pacini; Robin Foa; Alessandro Pulsoni; Riccardo Dalla Favera; Stefano Pileri
Journal:  Lancet       Date:  2004-06-05       Impact factor: 79.321

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  72 in total

Review 1.  Hairy cell leukemia: present and future directions.

Authors:  Robert J Kreitman
Journal:  Leuk Lymphoma       Date:  2019-05-09

Review 2.  Hairy cell leukemia: update and current therapeutic approach.

Authors:  Latif Salam; Omar Abdel-Wahab
Journal:  Curr Opin Hematol       Date:  2015-07       Impact factor: 3.284

3.  Tumor Type-Agnostic Treatment and the Future of Cancer Therapy.

Authors:  Luis E Raez; Edgardo S Santos
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

Review 4.  Immunoconjugates and new molecular targets in hairy cell leukemia.

Authors:  Robert J Kreitman
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

Review 5.  Hairy Cell Leukaemia.

Authors:  Matthew Cross; Claire Dearden
Journal:  Curr Oncol Rep       Date:  2020-04-16       Impact factor: 5.075

6.  Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.

Authors:  Mauricio Burotto; Maryalice Stetler-Stevenson; Evgeny Arons; Hong Zhou; Wyndham Wilson; Robert J Kreitman
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

7.  Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome.

Authors:  Evgeny Arons; Sharon Adams; David J Venzon; Ira Pastan; Robert J Kreitman
Journal:  Br J Haematol       Date:  2014-06-13       Impact factor: 6.998

Review 8.  Update on the biology and treatment options for hairy cell leukemia.

Authors:  Preetesh Jain; Naveen Pemmaraju; Farhad Ravandi
Journal:  Curr Treat Options Oncol       Date:  2014-06

Review 9.  Immunoconjugates in the management of hairy cell leukemia.

Authors:  Robert J Kreitman; Ira Pastan
Journal:  Best Pract Res Clin Haematol       Date:  2015-10-09       Impact factor: 3.020

Review 10.  Hairy cell leukemia: Past, present and future.

Authors:  Bartlomiej M Getta; Jae H Park; Martin S Tallman
Journal:  Best Pract Res Clin Haematol       Date:  2015-10-21       Impact factor: 3.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.